Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | CASR | P41180 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219867 | 0.86 | CASR (0.59) | CASRHTR1ASLC6A2OPRM1DRD3 | |
| SCHEMBL2217426 | 0.82 | CASR (0.50) | CASRHTTHTR1AADRA2AADORA3 | |
| Hydrochloric Acid SCHEMBL2837888 | 0.77 | KDM4E (0.41) | MEN1KMT2ASMN1; SMN2HTTCYP3A4 | |
| SCHEMBL13384263 | 0.75 | ADORA3 (0.38) | MEN1KMT2ASMN1; SMN2HTTADORA3 | |
| SCHEMBL14469653 | 0.75 | CASR (0.56) | MEN1KMT2ACASRSMN1; SMN2HTT | |
| SCHEMBL2780530 | 0.74 | POLB (0.41) | MEN1KMT2ASMN1; SMN2ADORA3CYP1A2 | |
| SCHEMBL17622 | 0.72 | CXCR2 (0.42) | MEN1KMT2ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL2217384 | 0.71 | HPGD (0.56) | CASRSMN1; SMN2HTTLMNADRD3 | |
| SCHEMBL3657245 | 0.71 | HPGD (0.56) | CASRSMN1; SMN2HTTLMNADRD3 | |
| SCHEMBL672597 | 0.71 | NOTUM (0.42) | MEN1KMT2ACYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | claimed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | claimed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2009051718-A2 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | CASR, CALCR, RYR1 | MEN1 2708/4885KMT2A 4757/4885CASR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.